Defunct Company
Total Trials
39
As Lead Sponsor
36
As Collaborator
3
Total Enrollment
6,428
NCT00617526
Naïve HIV POC Monotherapy Trial
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2008
Completion: Aug 31, 2008
NCT00741442
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
Start: Jul 31, 2008
Completion: Sep 30, 2009
NCT00955981
Gout Dose Response Study
Start: Jul 31, 2009
Completion: Sep 30, 2011
NCT01001338
Allopurinol Combination Study
Start: Oct 31, 2009
Completion: Aug 31, 2016
NCT01391325
Allopurinol Outcome Study
Phase: Phase 4
Start: Jul 31, 2011
Completion: Mar 31, 2013
NCT01493531
Combining Lesinurad With Allopurinol in Inadequate Responders
Phase: Phase 3
Start: Dec 31, 2011
Completion: Jul 31, 2014
NCT01508702
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Start: Jan 31, 2012
Completion: Nov 30, 2013
NCT01510158
Completion: Aug 31, 2014
NCT01510769
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Completion: Jun 30, 2014
NCT01650246
Open-Label Lesinurad Monotherapy Extension Study in Gout
Start: Aug 31, 2012
NCT01744379
Single and Multiple Dose Study in Japanese
Phase: Phase 1
Start: Dec 31, 2012
Completion: May 31, 2013
NCT01808131
Lesinurad and Allopurinol Combination Extension Study in Gout
Start: Feb 28, 2013
Completion: Nov 30, 2016
NCT01808144
Lesinurad and Febuxostat Combination Extension Study in Gout
Start: Mar 1, 2013
Completion: Oct 6, 2016
NCT01872832
Single and Multiple Dose Study in Japanese Subjects
Start: Jun 30, 2013
NCT01883167
RDEA3170 and Febuxostat Drug Interaction Study
Completion: Dec 31, 2013
NCT01884272
NSAID Drug Interaction Study
Completion: Oct 31, 2013
NCT01908257
Lesinurad Interaction Study With Ranitidine
Start: Jul 31, 2013
NCT01910506
RDEA3170 AME Study
Start: Aug 31, 2013
NCT01927198
RDEA3170 Monotherapy in Subjects With Gout
NCT02028689
Metformin and Furosemide Drug-Drug Interaction Study
Start: Oct 31, 2013
Completion: Jan 31, 2014
NCT01982201
Antacid Interaction Study
Start: Nov 30, 2013
Completion: Mar 31, 2014
NCT01986556
Lesinurad Tablet Relative Bioavailability
Completion: May 31, 2014
NCT02078219
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Role: Collaborator
Start: Jan 5, 2014
Completion: Mar 13, 2015
NCT02039700
Bioavailability of Lesinurad and Intravenous [14C]Lesinurad
Start: Jan 31, 2014
Completion: Apr 30, 2014
NCT02127775
Lesinurad Tablet Bioequivalence
Start: Apr 30, 2014
NCT02219516
Mild, Moderate and Severe Renal Impairment Study
Start: Aug 1, 2014
Completion: May 13, 2016
NCT02246673
RDEA3170 and Febuxostat Combination Study in Gout Subjects
Start: Oct 31, 2014
Completion: Feb 29, 2016
NCT02279641
RDEA3170 and Allopurinol Combination Study in Gout Subjects
Start: Nov 1, 2014
Completion: Sep 11, 2015
NCT02336594
RDEA3170 Bioavailability Study
Start: Nov 30, 2014
Completion: Mar 31, 2015
NCT02317861
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
Phase: Phase 1/2
Start: Dec 31, 2014
Completion: Jun 30, 2015
NCT02393560
DECT Study in Allopurinol-Treated Gout Patients
Phase: N/A
Start: Apr 30, 2015
Completion: Oct 31, 2016
NCT02398448
IVIVR Assessing PK Parameters Used to Establish Bioequivalence
Completion: Sep 30, 2015
NCT02448368
RDEA3170 Tablet and Capsule Bioavailability Study
Start: May 1, 2015
Completion: Jan 29, 2016
NCT02498652
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
Start: Jul 28, 2015
Completion: Jun 2, 2016
NCT02581553
Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability
Start: Oct 31, 2015
NCT02608710
RDEA3170 PK/PD Study
Start: Nov 30, 2015
Completion: Apr 30, 2016
NCT02888054
Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
Start: Aug 30, 2016
Completion: Feb 1, 2017
NCT03272425
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.
Start: Aug 14, 2017
Completion: Oct 4, 2017
NCT05297097
The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers
Start: Mar 1, 2022
Completion: Dec 30, 2022